Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA

뉴스 본문을 불러오고 있어요.

Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA | 웨이프 WAPE

Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA

기사 요약

관련 종목

댓글 —